SLC6A3 antibody (N-Term)
Quick Overview for SLC6A3 antibody (N-Term) (ABIN928031)
Target
See all SLC6A3 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- N-Term
-
Purification
- Purified
-
Immunogen
- SLC6 A3 antibody was raised in rabbit using the N terminal of SLC6 3 as the immunogen
-
-
-
-
Application Notes
-
WB: 0.2-1 µg/mL
Optimal conditions should be determined by the investigator. -
Comment
-
SLC6A3 Blocking Peptide, (ABIN939086), is also available for use as a blocking control in assays to test for specificity of this SLC6A3 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- SLC6A3 (Solute Carrier Family 6 (Neurotransmitter Transporter, Dopamine), Member 3 (SLC6A3))
-
Alternative Name
- SLC6A3
-
Background
- This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence. Synonyms: Polyclonal SLC6A3 antibody, Anti-SLC6A3 antibody, solute carrier family 6, neurotransmitter transporter, dopamine, member 3 antibody, DAT antibody, DAT1 antibody.
-
Pathways
- Dopaminergic Neurogenesis
Target
-